TY - JOUR
T1 - Potential role of indole-3-propionic acid in tuberculosis
T2 - current perspectives and future prospects
AU - Baral, Tejaswini
AU - Johnson, Aieshel Serafin
AU - Unnikrishnan, Mazhuvancherry Kesavan
AU - Manu, Mohan K.
AU - Saravu, Kavitha
AU - Udyavara Kudru, Chandrashekar
AU - Abdulsalim, Suhaj
AU - Singh, Jitendra
AU - Mukhopadhyay, Chiranjay
AU - Rao, Mahadev
AU - Miraj, Sonal Sekhar
N1 - Publisher Copyright:
© 2025 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2025
Y1 - 2025
N2 - Introduction: Indole-3-propionic acid (IPA), a tryptophan catabolite derived from gut bacterial metabolism, has been identified as a functional link between the gut microbiome and tuberculosis. Area covered: IPA has gained ample attention over the past two decades on account of its multiple physiological roles, besides being both detectable and quantifiable. IPA is well studied across different health conditions, including cardiovascular and neurological conditions. IPA blocks tryptophan synthesis in Mycobacterium by binding to the allosteric tryptophan-binding site of TrpE, thereby threatening Mycobacterium survival due to tryptophan deficit. Expert opinion: Characterizing IPA would enable its use as a tool to investigate the pathophysiology of tuberculosis. Integrating ‘OMICS’ techniques (through next-generation sequencing) along with targeted microbial metabolomics may help explore the possible association of serum IPA levels with TB in patients. This will aid in identifying IPA-producing gut microbes and selecting probiotic strains as a microbiome-targeting adjunct therapy, eventually enhancing our understanding of the molecular dynamics of the pathophysiology of tuberculosis in the context of the microbiome.
AB - Introduction: Indole-3-propionic acid (IPA), a tryptophan catabolite derived from gut bacterial metabolism, has been identified as a functional link between the gut microbiome and tuberculosis. Area covered: IPA has gained ample attention over the past two decades on account of its multiple physiological roles, besides being both detectable and quantifiable. IPA is well studied across different health conditions, including cardiovascular and neurological conditions. IPA blocks tryptophan synthesis in Mycobacterium by binding to the allosteric tryptophan-binding site of TrpE, thereby threatening Mycobacterium survival due to tryptophan deficit. Expert opinion: Characterizing IPA would enable its use as a tool to investigate the pathophysiology of tuberculosis. Integrating ‘OMICS’ techniques (through next-generation sequencing) along with targeted microbial metabolomics may help explore the possible association of serum IPA levels with TB in patients. This will aid in identifying IPA-producing gut microbes and selecting probiotic strains as a microbiome-targeting adjunct therapy, eventually enhancing our understanding of the molecular dynamics of the pathophysiology of tuberculosis in the context of the microbiome.
UR - https://www.scopus.com/pages/publications/105001933582
UR - https://www.scopus.com/pages/publications/105001933582#tab=citedBy
U2 - 10.1080/14728222.2025.2482548
DO - 10.1080/14728222.2025.2482548
M3 - Review article
AN - SCOPUS:105001933582
SN - 1472-8222
VL - 29
SP - 171
EP - 178
JO - Expert Opinion on Therapeutic Targets
JF - Expert Opinion on Therapeutic Targets
IS - 3
ER -